Aurinia Pharmaceuticals Inc.(AUPH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #200 of 2,879 stocksTOP 10%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AUPH Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Aurinia Pharmaceuticals Inc. (AUPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUPH at 73.3/100 on a 32-signal composite quality model, placing it at rank #200 of 2,879 stocks — the top 10% of the AI-ranked universe. AUPH scores in the top quartile across profitability (94.1), balance sheet strength (92.9), free cash flow (91.1). Areas of concern include revenue scale (28.8) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Aurinia Pharmaceuticals Inc. reports quarterly revenue of $77.7M, net income of $34.4M, an operating margin of 53.3%. Top institutional holders of AUPH by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock,, NEA Management Company,, based on the most recent SEC filings. AUPH trades on the Nasdaq exchange and files with the SEC under CIK 1600620. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aurinia Pharmaceuticals Inc. directly from SEC EDGAR. Aurinia Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 73.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving AUPH's Business? Latest 10-Q Breakdown
AI-extracted from Aurinia Pharmaceuticals Inc.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net product sales of LUPKYNIS grew 23% YoY to $73.6M; net income jumped 47% to $34.4M on strong margin expansion and valuation allowance release.
Biggest Revenue Drivers
Total revenue: $77.7M+24% YoY
Increase in LUPKYNIS cartons sold to specialty pharmacies driven by further lupus nephritis market penetration.
Manufacturing services provided to Otsuka for sharing capacity of the Monoplant.
Largest Expense Items
Decrease primarily due to lower sales of LUPKYNIS inventory to Otsuka, which has low gross margin.
Increase driven by severance for departing officers; offset by lower professional fees from 2024 restructuring.
Increase due to severance expense and higher employee costs to support development activities.
Watch Items from the Filing
- Three customers (two specialty pharmacies, one distributor, and Otsuka) represent 100% of revenue; customer concentration risk remains high.
- Announced Kezar Life Sciences acquisition for $6.955/share plus CVR on March 30, 2026; expected to close Q2 2026, adding development complexity.
- Valuation allowance on deferred tax assets released in Q1 2026; company now expects to realize benefit, lowering future effective tax rate.
- Management transition: four senior officers departed March 2026; new CEO, CFO, and COO appointed March 23, 2026; transition costs included severance.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$77.7M
Net Income
Q1 2026
$34.4M
Free Cash Flow
Q1 2026
$32.6M
Operating Margin
Q1 2026
53.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+20.4% YoYNet Income
+4851.8% YoYOperating Income
+2338.4% YoYEPS (Diluted)
+5075.0% YoYTotal Assets
+36.5% YoYOp. Cash Flow
+205.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $283.1M +20.4% | $235.1M +34.0% | $175.5M +31.0% | $134.0M +193.9% | $45.6M -9.0% | $50.1M |
| Net Income | $287.2M +4851.8% | $5.8M +107.4% | $-78.0M +27.9% | $-108.2M +40.2% | $-181.0M -76.3% | $-102.7M |
| Operating Income | $104.9M +2338.4% | $-4.7M +94.9% | $-91.7M +17.7% | $-111.5M +38.3% | $-180.7M -73.3% | $-104.3M |
| EPS (Diluted) | $2.07 +5075.0% | $0.04 +107.4% | $-0.54 +28.9% | $-0.76 +45.7% | $-1.40 -60.9% | $-0.87 |
| Total Assets | $751.6M +36.5% | $550.6M +0.5% | $548.1M +16.4% | $470.9M -13.3% | $543.4M +17.2% | $463.7M |
| Operating Cash Flow | $135.7M +205.6% | $44.4M +232.7% | $-33.5M +57.9% | $-79.5M +49.6% | $-157.7M -125.7% | $-69.9M |
AI Insight: AUPH Financial Trends
Revenue growth accelerating and profitability sustained, but Q4 2025 net income spike suggests one-time gains masking underlying operational trends.
• Revenue grew 37% from Q2 2024 ($57M) to Q1 2026 ($78M), with consistent growth in last four quarters.
• Operating income turned positive and expanded to $41M in Q1 2026, up from $-2M in Q4 2024.
• Operating cash flow averaged $33M over last four quarters, supporting cash generation and deleveraging.
⚠ Q4 2025 net income of $211M far exceeded operating income of $33M, signaling material non-operating gains requiring clarification.
⚠ Equity increased 55% from Q2 2024 ($365M) to Q4 2025 ($581M), then modestly declined to $568M in Q1 2026.
AI Insight: AUPH Ratio Trends
Operating margin surged to 53.3% in Q1 2026, capping a dramatic turnaround from -2.6% two years prior—driven by profitable scale in core business.
• Operating margin expanded from -2.6% in Q2 2024 to 53.3% in Q1 2026; Q3 2025 through Q1 2026 all exceeded 40%.
• ROIC climbed from -1.7% in Q2 2024 to 29.2% in Q1 2026, reflecting sustained capital efficiency improvement over past two years.
• TTM net profit margin at 100% with ROIC at 21.9%, signaling substantial profitability relative to invested capital.
⚠ ROE spiked to 145% in Q4 2025 then fell sharply to 24.2% in Q1 2026—suggests significant seasonality or one-time item distortion.
⚠ Q4 2025 NPM not disclosed; ROA also missing—limits visibility into that quarter's true profitability profile.
Get alerted when AUPH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aurinia Pharmaceuticals Inc. including:
Top Institutional Holders of AUPH
TANG CAPITAL MANAGEMENT LLC
$181.2M12,229,500 shBlackRock, Inc.
$116.3M7,845,521 shNEA Management Company, LLC
$58.8M3,969,834 shTWO SIGMA INVESTMENTS, LP
$50.8M3,428,705 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$48.7M3,284,368 shSTATE STREET CORP
$37.5M2,527,099 shMORGAN STANLEY
$33.1M2,232,548 shMARSHALL WACE, LLP
$27.8M1,874,597 shRENAISSANCE TECHNOLOGIES LLC
$24.7M1,663,835 shD. E. Shaw & Co., Inc.
$23.3M1,572,983 sh
| Fund | Value | Shares |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $181.2M | 12,229,500 |
| BlackRock, Inc. | $116.3M | 7,845,521 |
| NEA Management Company, LLC | $58.8M | 3,969,834 |
| TWO SIGMA INVESTMENTS, LP | $50.8M | 3,428,705 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $48.7M | 3,284,368 |
| STATE STREET CORP | $37.5M | 2,527,099 |
| MORGAN STANLEY | $33.1M | 2,232,548 |
| MARSHALL WACE, LLP | $27.8M | 1,874,597 |
| RENAISSANCE TECHNOLOGIES LLC | $24.7M | 1,663,835 |
| D. E. Shaw & Co., Inc. | $23.3M | 1,572,983 |
More Healthcare Companies
View all Healthcare →Put AUPH on your watchlist
Track score changes the day Aurinia Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AUPH a good stock to buy?
13F Pro's AI-powered analysis of Aurinia Pharmaceuticals Inc. (AUPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AUPH are available on the AUPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AUPH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AUPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aurinia Pharmaceuticals Inc.'s investment landscape.